Author of

• 28971

  +

  Lunch & Poster Display session (ID 58)

  • Event: ELCC 2019
  • Type: Poster Display session
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1

  • 29037

    +

    79P - Tissue microarray analysis on prognostic value of coexpression of RUNX3 and trimethylated histone H3 lysine 27 in surgically resected patients with stage I non-small cell lung cancer (ID 442)

    12:30 - 13:00  |  Presenting Author(s): Xiaohui Chen
    • Abstract
    • Slides

    Background
    

    Lung cancer is still the leading cause of cancer-related deaths in both sexes in China and worldwide. Although many surgically resected patients shared the same histology and pathologic TNM stage, their prognosis had varied a lot. For within the stage-Ipatients who had received radical surgery of lung cancer, nearly one-third of them suffered from postoperative relapse or distant metastasis. In the present study, we sought to investigate the potential interrelationships of expression of RUNX3, H3K27me3 and its methyltransferase EZH2 in NSCLC patients, their correlation with clinicopathologic parameters, and the prognostic significance as well.

    a9ded1e5ce5d75814730bb4caaf49419 Methods
    

    A total of 208 NSCLC patients and block samples who had never received other therapies before were collected and built into tissue microarrays (TMA). Protein level of RUNX3, H3K27me3, EZH2 were detected and evaluated with immunohistochemistryand western blotting to determine their expressions and mutual correlations.

    20c51b5f4e9aeb5334c90ff072e6f928 Results
    

    Co-expression of RUNX3 and H3K27me3 stood a vital significance in the prediction of better outcome and longer OS in early-stage NSCLC, especially pTNM stage-I(P = 0.0124). Correlation analysis demonstrated that non-coexpression of RUNX3 and H3K27me3 was significantly associated with male sex (P = 0.037), high ECOG PS (P = 0.000), smoker (P = 0.001), postoperative relapse (P = 0.000), postoperative distant metastasis (P = 0.048), non-nuclear expression of RUNX3 (P = 0.000) and low EZH2 expression (P = 0.016) while had nothing to do with age (P = 0.918), histology (P = 0.145), BMI (P = 0.300), lymphatic vessels involvement (P = 0.246), pleural involvement (P = 0.811), vascular involvement (P = 0.144), T staging (P = 0.189), lymph node involvement (P = 0.152), mediastinal lymph node involvement (P = 0.608), M staging (P = 0.667), TNM staging (P = 0.227, P = 0.231), resectibility (P = 0.850), depth of invasion (P = 0.245), serum CEA level (P = 0.174) or Ki-67 expression (P = 0.947).

    fd69c5cf902969e6fb71d043085ddee6 Conclusions
    

    Coexpression of RUNX3 and H3K27me3 is a good marker as survival gain to discriminiate whether or not TNM stage-INSCLC patients would have a better survival.

    b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study
    

    The authors.

    213f68309caaa4ccc14d5f99789640ad Funding
    

    Has not received any funding.

    682889d0a1d3b50267a69346a750433d Disclosure
    

    All authors have declared no conflicts of interest.

    cffcb1a185b2d7d5c44e9dc785b6bb25

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.